Allotment of 2306372 securities pursuant to Preferential Issue at its meeting held on January 16, 2026
As filed · Eris Lifesciences Limited has informed the Exchange regarding allotment of 2306372 securities pursuant to Preferential Issue at its meeting held on January 16, 2026
What happened
FactEris Lifesciences Limited has informed the Exchange regarding allotment of 2306372 securities pursuant to Preferential Issue at its meeting held on January 16, 2026. LIFESCIENCES LIMITED (“COMPANY”) IN RELATION TO PREFERENTIAL ISSUE. INR 10 (Indian Rupees Ten) each (“Sale Shares”) of Swiss Parenterals Limited (“Swiss”) held by him.
Why it matters
CapitSignal interpretationShares are issued to named investors at a set price, diluting existing holders and changing who sits on the register.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
WithdrawnWith an EBIDTA of Rs. 180-200 cr.
Our International Business is well on its way to achieve Rs. 1,000 cr. revenue by 2029/ 2030
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Who the allottees are
- Issue price versus market price
- Lock-in period on the new shares
- We see an EBIDTA potential of at least Rs. 50 cr. p.a. from the additional market opportunity (management committed by FY27)
- VE A NET-DEBT-TO-EBIDTA RATIO OF < 1.5x BY DEC 2026 (management committed by Q4 FY26)
Evidence
- Eris Lifesciences Limited has informed the Exchange regarding allotment of 2306372 securities pursuant to Preferential Issue at its meeting held on January 16, 2026(opens the original filing in a new tab)
- Earlier statement · FY27
- Latest statement · FY27
- Earlier statement · FY27
How CapitSignal classified this
- Reasoning:
- PREFERENTIAL_ALLOTMENT base 66; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%